In the high-stakes battlefield of oncology, few proteins have been as notoriously difficult to defeat as MYC. Long recognized as a primary driver of aggressive cell growth, MYC is abnormally active in the majority of human cancers. For decades, it has been the "white whale" of drug development—a target so vital to cancer’s survival that it seemed impossible to suppress without causing catastrophic damage to healthy cells.
However, a groundbreaking study published in the journal Genes & Development has shifted the paradigm. Researchers at Oregon Health & Science University (OHSU) have unveiled a secondary, previously unknown function of the MYC protein: it acts as a molecular mechanic, actively repairing damaged DNA within tumor cells. This discovery not only explains why many aggressive cancers—particularly pancreatic cancer—are so resistant to chemotherapy and radiation, but it also offers a potential new "Achilles’ heel" for scientists to exploit in future therapies.
The Mechanics of Resilience: A New Understanding of MYC
For years, the scientific consensus regarding MYC was straightforward: it was a transcriptional regulator. In healthy cells, it acts as a gatekeeper, switching genes on and off to regulate growth and metabolism. In cancer, this process goes haywire, with MYC perpetually stuck in the "on" position, driving the runaway cell division that characterizes malignant tumors.
The new research, led by senior author Rosalie Sears, Ph.D., and first author Gabriel Cohn, Ph.D., reveals that MYC’s influence extends far beyond the nucleus’s gene-regulation machinery. When a cancer cell experiences "replication stress"—the natural consequence of rapid growth—or when it is hit with the DNA-shattering force of chemotherapy or radiation, a modified version of the MYC protein physically relocates to the site of the damage.
Once at the scene of the "accident," MYC acts as a scaffold or recruitment center, drawing in the various repair proteins needed to mend broken DNA strands. By patching these breaks, MYC allows the tumor cell to survive environmental stressors that would otherwise trigger programmed cell death (apoptosis).
"Our work shows that MYC isn’t just helping cancer cells grow—it’s also helping them survive some of the very treatments designed to kill them," explains Dr. Sears, who serves as the Krista L. Lake Chair in Cancer Research and co-director of the OHSU Brenden-Colson Center for Pancreatic Care.
A Chronology of Discovery: From Observation to Insight
The path to this discovery was paved through years of rigorous observation within the OHSU labs. The journey can be categorized into three distinct phases of inquiry:
Phase 1: Identifying the Anomaly
Early observations suggested that certain aggressive tumors were able to withstand higher-than-normal levels of chemotherapy. While researchers initially suspected genetic mutations were responsible for this resistance, the OHSU team began to look closer at the protein environment of these cells. They noted that in cancers with high MYC activity, the cells appeared to be recovering from DNA-damaging agents with unusual efficiency.
Phase 2: The "Non-Canonical" Breakthrough
Gabriel Cohn, then a researcher in the Sears lab and currently a postdoctoral researcher at the University of Würzburg, spearheaded the effort to track MYC’s movement. Using advanced imaging and cellular analysis, the team observed that when DNA was artificially damaged in a laboratory setting, MYC did not merely stay in the nucleus to regulate gene expression. Instead, it mobilized to the damaged sites. This confirmed that MYC was performing a "non-canonical" role—a function entirely separate from its traditional duty as a gene-transcription regulator.
Phase 3: Clinical Validation
The team corroborated these laboratory findings by analyzing tumor samples from patients. They found a direct correlation: tumors with the highest MYC activity showed the most robust DNA repair signatures and, correspondingly, the poorest clinical outcomes for patients. This established a clear link between the protein’s mechanical repair function and the clinical failure of standard-of-care treatments.
Supporting Data: Why Pancreatic Cancer is the Primary Target
The findings are particularly alarming—and revealing—when applied to pancreatic cancer. As one of the most lethal malignancies, pancreatic cancer is characterized by a hostile microenvironment. Tumor cells are often deprived of nutrients, lack adequate blood supply, and are subject to massive replication stress.
According to Dr. Cohn, the survival of these cells is a testament to their efficiency in handling DNA damage. "Tumor cells in these cancers experience significant DNA damage and replication stress, yet they continue to survive and grow," he notes. "Our work suggests that MYC helps these cells cope with that stress by actively promoting DNA repair."
The data collected by the OHSU team highlights three critical factors:
- Enhanced Repair Efficiency: Cancer cells expressing the modified form of MYC consistently repaired induced DNA damage faster than those without it.
- Survival Under Stress: Under conditions that typically kill healthy cells, MYC-positive cancer cells exhibited a distinct survival advantage.
- Clinical Correlation: Patient data confirms that tumors with high levels of this modified MYC are significantly more likely to develop resistance to chemotherapy and radiation, explaining why these patients often face a grim prognosis.
Official Responses and the "Undruggable" Dilemma
The scientific community has long viewed MYC as "undruggable." The protein lacks a clear pocket or "binding site" where a traditional small-molecule drug could lock in and inhibit its function. Furthermore, because MYC is essential for the healthy function of many organs, systemic inhibition could potentially lead to severe side effects.
However, the OHSU research team suggests that by identifying this specific, non-canonical repair role, they may have found a bypass. By targeting the mechanism by which MYC assists in DNA repair—rather than trying to shut down the entire MYC protein—scientists might be able to selectively sensitize cancer cells to treatment while leaving healthy cellular functions largely intact.
"If we can interfere with MYC’s role in DNA repair—without shutting down everything MYC does in healthy cells—we may be able to make cancer cells more vulnerable to treatment," Dr. Sears says.
This strategy is already moving from the bench to the bedside. OHSU is currently involved in a "window of opportunity" clinical trial testing a first-in-class MYC inhibitor called OMO-103. In this trial, patients with advanced pancreatic cancer receive the drug prior to surgical intervention. By taking biopsies before and after the administration of OMO-103, researchers can gain an unprecedented, real-time look at how inhibiting MYC alters the tumor’s molecular landscape.
Implications for Future Cancer Therapy
The implications of this discovery are profound. For decades, oncologists have relied on the "blunt force" approach of chemotherapy and radiation—essentially trying to smash the DNA of cancer cells harder than the cells can repair it. This new research suggests that MYC is the "shield" that allows cancer cells to withstand that blow.
1. Precision Targeting
If clinicians can determine a patient’s MYC repair activity through diagnostic testing, they may be able to personalize treatment regimens. Patients with high MYC-repair signatures might be prioritized for trials involving MYC inhibitors in combination with standard chemotherapy, effectively stripping the tumor of its protective armor before delivering the killing blow.
2. Overcoming Resistance
One of the greatest challenges in oncology is acquired resistance. Patients often start treatment with a positive response, only for the cancer to return as a more aggressive, treatment-resistant version. By blocking the DNA repair pathway, researchers hope to prevent these cells from recovering, effectively cutting off the escape route for the cancer.
3. A New Class of Combination Therapies
The future of oncology likely lies in combination therapies. This discovery opens the door for drugs that specifically inhibit the interaction between MYC and the repair proteins it recruits. By "denying" the tumor its ability to repair its own DNA, standard chemotherapies could become significantly more effective, potentially allowing for lower, less toxic doses.
Conclusion
The discovery at OHSU serves as a reminder that cancer is not merely a static disease of runaway growth; it is a dynamic, adaptive adversary. By identifying that MYC acts as a repair specialist, the researchers have pulled back the curtain on one of the most effective survival strategies in the cancer cell’s arsenal.
While the "undruggable" nature of MYC still presents a significant hurdle, the shift toward targeting its specific, non-canonical roles provides a beacon of hope. As clinical trials like the one testing OMO-103 continue to unfold, the scientific community moves one step closer to transforming some of the most lethal, resistant cancers into manageable, and perhaps even curable, conditions. The work of Dr. Sears, Dr. Cohn, and their colleagues at the Knight Cancer Institute represents a pivotal moment in our understanding of cancer’s resilience—and our growing capability to dismantle it.
The study was supported by the National Cancer Institute of the National Institutes of Health (award numbers NCI U01CA294548, U01CA224012, U01CA278923, R01CA186241, R01CA287672, R21CA263996), the Department of Defense (award PA210068), the Brenden-Colson Center for Pancreatic Care, the Krista L. Lake Endowed Chair, and the Knight Cancer Institute.
